Text Size

Prostate Cancer Nomograms : Disclaimer

The prediction tools, also known as prognostic nomograms, located on the MSKCC Web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.

Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.

MSKCC makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSKCC does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect.

Use of the prediction tools does not create an express or implied physician-patient relationship. MSKCC does not endorse or claim validity for the prediction tools found on the MSKCC Web site. The activities and products of MSKCC and its developers and agents (collectively MSKCC) are not endorsed by our past, present, or future employers. MSKCC does not record specific prediction tool user information and does not contact users of the prediction tools.

You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that neither MSKCC nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.

I accept all of the above terms by clicking here or by any further use of this service.
I do not accept all of the above terms.

Prostate Cancer Nomograms: Hormone Refractory

For patients with advanced, metastatic prostate cancer that has been treated maximally with hormone therapy to control the effects of the male hormone, androgen. The nomogram predicts the survival probability one to two years later. To learn more, visit our frequently asked questions.

CalculateClearEnter Your Information

To gather the information required below, download our PDF worksheet.

(40 to 85 yrs)
KPS value, assigned by a physician, nearest to the planned treatment start date or today's date.
HGB value from the laboratory report nearest to the planned treatment start date or today's date.
(6 to 17 g/dl)
PSA value from the laboratory report closest to the planned treatment start date or today's date.
(0.01 and 8450 ng/ml)
LDH value from the laboratory report closest to the planned treatment start date or today's date.
(116 to 1955 IU/L)
ALK value from the laboratory report closest to the planned treatment start date or today's date.
(19 to 3079 IU/L)
Albumin value from the laboratory report closest to the planned treatment start date or today's date.
(2.6 to 5.2 g/dl)

Learn More About Your Results

Hormone Refractory Survival Probability

This nomogram is for those individuals who have advanced metastatic prostate cancer and have been treated maximally with hormone therapy to counteract the effects of the male hormone androgen. Hormone therapy usually consists of an LH-RH antagonist such as Luprolide or Goserelin, as well as antiandrogens such as bicalutamide and ketoconazole. The nomogram estimates the probability that the patient will be alive one and two years later and provides a median estimate of survival in months (the length of time that half of such patients will still be alive).

Supporting Publication

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002 Oct 1;20(19):3972-82.